Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 9Anus Neoplasms 2Rectal Neoplasms 1HIV Infections 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Polyps 1Colonic Neoplasms 1Colitis, Ulcerative 1Anal Canal Carcinoma 1

Interventions

Capecitabine 13Fluorouracil 12Oxaliplatin 9Nivolumab 9Radiotherapy 8Leucovorin 8Cetuximab 8Magnetic Resonance Spectroscopy 6Irinotecan 5pembrolizumab 4encorafenib 4Surgical Procedures, Operative 4Sigmoidoscopy 4Radiotherapy, Intensity-Modulated 4Surveys and Questionnaires 3Standard of Care 3Specimen Handling 3Biopsy 3Bevacizumab 3dostarlimab 2dehydroftorafur 2atezolizumab 2XELOX 2X-Rays 2Observation 2Magnetic Resonance Imaging 2Immunoglobulin G 2Folfox protocol 2Drug Therapy 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Rectal Neoplasms × Colonoscopy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡